中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (6): 444-446.doi: 10.12144/zgmfskin202606444

• 病例报告 • 上一篇    下一篇

氘可来昔替尼治疗红皮病型银屑病一例

魏婷1,2，3,张帆1,2,张园1,2,田洪青1,2   

  1. 1山东第一医科大学附属皮肤病医院,山东济南,250022;2山东省皮肤病性病防治研究所,山东济南,250022;3泰安市中心医院,山东泰安,271000
  • 出版日期:2026-06-15 发布日期:2026-06-04

Deucravacitinib for the treatment of erythrodermic psoriasis: a case report

WEI Ting1,2,3, ZHANG Fan1,2, ZHANG Yuan1,2, TIAN Hongqing1,2   

  1. 1 Dermatology Hospital Affiliated of Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China; 3 Taian Central Hospital, Taian 271000, China
  • Online:2026-06-15 Published:2026-06-04

PDF (PC)

3

摘要： 本文报道一例氘可来昔替尼成功治疗红皮病型银屑病患者。患者,男,75岁。躯干、四肢皮肤反复发作红斑、斑块、脱屑8年，累及全身5年，复发2个月。既往间断口服环孢素治疗，效果不佳。给予氘可来昔替尼片6 mg口服，每日1次，4周后复诊，全身弥漫性暗红斑、脱屑消退，目前随访中。

关键词: 红皮病型银屑病, 氘可来昔替尼, JAK抑制剂

Abstract: We report a case of successful treatment with deucravacitinib in a patient with erythrodermic psoriasis. The patient was a 75-year-old male. He had experienced recurrent erythema, plaques, and desquamation on the trunk and extremities for 8 years, with generalized involvement for 5 years. The condition relapsed 2 months ago. He had been treated with oral cyclosporine intermittently, but the effect was unsatisfactory. He was given 6 mg of deucravacitinib orally once daily. Four weeks later, he returned for a follow-up visit, and the diffuse dark erythema and desquamation over the entire body had subsided. He is still under follow-up.

Key words: erythrodermic psoriasis, deucravacitinib, JAK inhibitors